GLP-1 is your gut's meal signal
Semaglutide: what its GLP-1 effect may mean
See what changed for people. Then check which problems and warnings could matter to you.
What Semaglutide may change for you
Researchers first made Semaglutide to help with blood sugar. They wanted a natural gut hormone that wouldn't fade in minutes.
Doctors call that hormone GLP-1. Your gut sends it out after a meal, and it helps your body handle the sugar.
That hormone's also how you know you've had enough. Semaglutide keeps that message going much longer.
You may know it as a type 2 diabetes drug. It'll also help some people lose weight.
In some people it's cut heart problems. In 2025 it was also approved for one serious liver disease: fat builds up in the liver, it swells, and scarring follows.
You can get it as a weekly shot. There's also a daily pill you'd swallow.
Your stomach may feel queasy at first. Nausea is the complaint you'll hear most.
Some people vomit, or get diarrhea or constipation. A few warnings are serious, and they're spelled out below.
Users also tell of changes studies haven't proved. Those accounts are on the effects page.
Every number you'll read here comes from a published paper. The bracket number after it tells you which one.
What Semaglutide can do to your stomach and eyes
Most trouble in the studies started in the gut. Nausea came first, then constipation, vomiting and diarrhea.
Most of it wasn't severe [8]. It bunched up in the weeks the dose was going up, then it'd usually pass.
Close to a third of patients had nausea, a safety review found [5]. It still judged the benefits bigger than the harms overall.
You'd also see gallbladder trouble more often. Pancreas and thyroid cancer stayed open questions.
Those cancers didn't come up often in the studies. With so few cases, nobody could say for sure, and you can't read that as all clear.
The thyroid worry didn't start in people. It started in rats and mice. Certain thyroid cells grew tumors in those animals.
That's why GLP-1 drugs carry the FDA's boxed warning, its strongest kind. A 2024 review in people turned up no clear rise [13].
Still, if you or a relative had a rare thyroid cancer, the drug may be ruled out. Tell your doctor if that's so.
SUSTAIN-6 was a heart study in high-risk people with diabetes. Some started with eye damage from diabetes, and once they began, their sugar dropped quickly.
In that group, eye problems came about 1.76 times as often on Semaglutide [2]. The researchers' math left them 95% sure that gap wasn't luck.
That's a comparison of two groups. Your own eyes may do something else entirely.
The Semaglutide effects page goes through each warning. It also covers what happens after you stop.
What Semaglutide changed in large studies
Researchers first hoped for better blood sugar and lower weight. Later studies checked hearts and kidneys too.
STEP 1 tested weight loss in adults without diabetes. By week 68, people getting the medicine had dropped 14.9% of their body weight on average [1].
A placebo is a dummy shot; there's no medicine in it. The placebo group lost 2.4%.
SUSTAIN-6 followed adults with type 2 diabetes and hearts already at high risk. On Semaglutide, fewer of them suffered heart attacks or strokes, or died of heart disease [2].
The researchers were 95% sure that drop wasn't luck. It sits beside the eye warning, not in place of it.
A second heart study followed 17,604 adults who had both heart disease and obesity. None of them had diabetes.
Heart attacks, strokes and heart deaths fell by 20% [3]. Again the math left researchers 95% sure it wasn't chance.
A kidney study took in people with type 2 diabetes and kidney disease. Serious kidney events fell by 24% [6].
That result also cleared the 95% bar against luck. Help this large is why you'll want to look hard at the harms.
The Semaglutide research page tells who was studied. It also says what the doctors measured.
What Semaglutide is approved to treat
Semaglutide's a prescription medicine, built that way from the start. It isn't a lab chemical sold for research.
Back in 2017, the FDA approved it for type 2 diabetes. A daily pill form won approval in 2019–2020.
In 2021 the FDA approved it for keeping weight down over the long haul [1]. Bigger studies then tested it against other illnesses.
After a heart study, doctors could prescribe it to lower the chance of heart attack and stroke [3]. After a kidney study, it was approved for kidney disease in type 2 diabetes [6].
In 2025 the FDA added a liver disease where fat buildup inflames and scars the liver. So doctors now have years of results in people.
Blood-sugar and weight studies enrolled tens of thousands of patients. Separate heart and kidney trials followed.
The heart study had 17,604 people [3]. The kidney study had 3,533 [6].
None of that makes the drug safe for you or anyone else. It does mean the harms were counted in real people.
A pharmacy mixes compounded Semaglutide itself; it isn't made at the drug company's plant. It isn't the approved product those studies tested.
That's why what the studies found doesn't carry over to compounded versions. Keep that in mind when you hear claims about them.
What each Semaglutide study can tell you
It's worth starting with what each study measured. STEP checked weight, and SUSTAIN-6 checked heart trouble.
A separate study checked serious kidney trouble. Safety reviews gathered the known harms.
Some questions still don't have firm answers. Hair shedding and later muscle strength are two of them.
Certain health facts may rule the medicine out. Thyroid cancer in the family, pregnancy and past pancreas trouble all count.
What users tell each other isn't a study. It shows you what people noticed, not what caused it.
A controlled study puts two groups side by side. That's a fairer test than one person's story.
The amounts tested in the papers aren't instructions. Your prescriber makes that call.
Read semaglutide hair loss about shedding. Read semaglutide muscle loss about strength.
You'll find every source on the Semaglutide references page. Bring the ones that worry you to your doctor.